Olivier Bohuon elected new chairman of LEO Pharma’s Board of Directors
At the Annual General Meeting in LEO Holding A/S on February 26th a unified Board of Directors elected former vice chairman Olivier Bohuon as new chairman of the Board of Directors of LEO Pharma following Jukka Pertola’s decision to leave the Board. Anders Ekblom was elected as new vice chairman. In addition, John Weeks decided to not seek
re-election.
“With Olivier Bohuon and Anders Ekblom we have two strong successors with extensive industry experience who can help set the direction for LEO Pharma’s future development and realize the company’s ambitious strategy towards 2025. Olivier Bohuon has profound knowledge from several leading positions in the global pharma industry and Anders Ekblom’s scientific background and comprehensive experience from the global life science sector is an ideal complement”, said Jukka Pertola, resigning chairman of LEO Pharma.
Jukka Pertola has been member of LEO Pharma’s Board of Directors since 2011 and chairman since 2016.
“Jukka Pertola has been instrumental in getting LEO Pharma to the position the company holds today and by manning the board with strong profiles and securing board succession. During his time as member and chairman of the Board of Directors, LEO Pharma has gone through a massive transformation turning the company into a global leader specialized in medical dermatology. I would like to express my sincere gratitude to Jukka for his contribution”, said Lars Olsen, chairman of the Board of Trustees of the LEO Foundation, also thanking John Weeks for his dedicated contribution as member of the Board of Directors at LEO Pharma since 2014.
Olivier Bohuon is External Director of the Board of Directors at Takeda plc, External Director of the Board of Directors of Smiths Group plc, a supervisory board member at Virbac SA, and member of the French National Pharmacy Academy and the French Academy of Technologies. From 2011 to May 2018 Bohuon served as CEO of medical equipment specialist Smith & Nephew Plc. Before that, he held positions as CEO at Laboratories Pierre Fabre and President of Pharmaceutical Products Division at Abbott Laboratories.
Anders Ekblom is a physician, board certified in anaesthesia and intensive care, dentist and Associate Professor in physiology at Karolinska Institute and a fellow of the Royal Swedish Academy of Engineering Sciences. His experience from the global biopharmaceutical industry includes positions as EVP Global Medicines Development at AstraZeneca Plc, CEO of AstraZeneca AB Sweden, Director of the Board at Mereo BioPharma Group Plc, Alligator Bioscience AB, and several other companies.
Contacts
Media Contacts
Head of Global External Communication
Henrik Kyndlev
hdtdk@leo-pharma.com
TEL +45 3140 6180
Corporate Communications Manager
Maia Fredtoft Soechting
mfddk@leo-pharma.com
TEL +45 3119 3559
About LEO Pharma
About LEO Pharma
LEO Pharma helps people achieve healthy skin. The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 5,500 people, serving 76 million patients in 130 countries. In 2018, the company generated net sales of DKK 10,410 million.
For more information, go to:
www.linkedin.com/company/leo-pharma or www.leo-pharma.com
Subscribe to releases from LEO Pharma
Subscribe to all the latest releases from LEO Pharma by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from LEO Pharma
Annual report 2023: LEO Pharma delivers 10% revenue growth and returns to positive EBITDA29.2.2024 14:00:00 CET | Pressemeddelelse
Ballerup, February 29, 2024. – LEO Pharma delivers a solid operational performance uplift with double-digit revenue growth and an EBITDA uplift of DKK 2.1 billion, corresponding to a 20%-points margin improvement. LEO Pharma exceeded our profitability guidance and hit the upper range of our revenue growth guidance provided in March 2023.
LEO Pharma announces positive phase 3 head-to-head data results from DELTA FORCE trial comparing delgocitinib cream with alitretinoin capsules in adults with severe chronic hand eczema (CHE)24.1.2024 08:00:00 CET | Pressemeddelelse
Delgocitinib cream demonstrated a superior reduction in Hand Eczema Severity Index (HECSI) score from baseline to Week 12 compared to alitretinoin capsules as its primary outcome measure. Delgocitinib cream also demonstrated superiority to alitretinoin capsules in all key secondary outcome measures, including Investigator’s Global Assessment (IGA)-CHE treatment success, health-related quality of life (HRQoL), and a lower number of treatment-emergent adverse events. DELTA FORCE is the first head-to-head phase 3 trial comparing a systemic and topical treatment for CHE.1 With only one treatment option currently approved for severe CHE and no approved optionsfor more moderate forms of the disease, there is a considerable unmet need for patients living with CHE.
LEO Pharma finalizes acquisition of key assets from Timber Pharmaceuticals23.1.2024 12:30:00 CET | Pressemeddelelse
Strategic acquisition to expand pipeline, accelerate growth, and meet unmet needs in medical dermatology.
LEO Pharma announces positive outcome of DELTA 3 open-label extension trial of delgocitinib cream in the treatment of adults with moderate to severe chronic hand eczema (CHE)30.10.2023 10:00:00 CET | Pressemeddelelse
Subjects who completed the 16-week twice-daily treatment regimen of delgocitinib cream or cream vehicle in the phase 3 DELTA 1 or DELTA 2 trials were offered to immediately enroll into the 36-week DELTA 3 extension trial.1 The DELTA 3 trial evaluated the long-term safety of twice-daily as needed treatment with delgocitinib cream for up to 36 weeks in adults with moderate to severe CHE.1 The long-term safety profile of delgocitinib cream was consistent with previous results from the DELTA 1 and 2 trials. Patients who entered the DELTA 3 trial after receiving delgocitinib cream in the DELTA 1 and DELTA 2 trials maintained similar levels of symptom relief and treatment success over an additional 36-week treatment regimen.
LEO Pharma provides update on the development program for izuforant20.10.2023 09:43:02 CEST | Pressemeddelelse
The Phase 2a/b international trial to evaluate the efficacy and safety of orally administered izuforant tablets compared with placebo tablets for up to 16 weeks of treatment in adults with moderate to severe AD did not meet the primary endpoint. As a result, LEO Pharma ends the program for izuforant and terminates the license agreement with JW Pharmaceutical. LEO Pharma remains committed to delivering value for patients living with atopic dermatitis and other skin diseases.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom